Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil
Rev. Soc. Bras. Med. Trop
; 52: e20180272, 2019. tab, graf
Article
en En
| LILACS
| ID: biblio-1041550
Biblioteca responsable:
BR1.1
ABSTRACT
Abstract INTRODUCTION:
Visceral leishmaniasis (VL) is fatal if not diagnosed and treated. This study aimed to estimate the cost-effectiveness of diagnostic-therapeutic alternatives for VL in Brazil.METHODS:
A decision model estimated the life expectancy and costs of six diagnostic-therapeutic strategies.RESULTS:
IT LEISH + liposomal amphotericin B emerged the best option, presenting lower costs and higher effectiveness. DAT-LPC + liposomal amphotericin B showed an incremental cost-effectiveness ratio of US$ 326.31 per life year.CONCLUSIONS:
These findings indicate the feasibility of incorporating DAT and designating liposomal amphotericin B as the first-line drug for VL in Brazil.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
LILACS
Asunto principal:
Anfotericina B
/
Análisis Costo-Beneficio
/
Leishmaniasis Visceral
/
Meglumina
/
Antiprotozoarios
Tipo de estudio:
Diagnostic_studies
/
Health_economic_evaluation
/
Prognostic_studies
Aspecto:
Patient_preference
Límite:
Humans
País/Región como asunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Rev. Soc. Bras. Med. Trop
Asunto de la revista:
MEDICINA TROPICAL
Año:
2019
Tipo del documento:
Article
País de afiliación:
Brasil
Pais de publicación:
Brasil